The FDA Fast Track designation and reaffirmed Q4 2026 data timeline for ANB033 in celiac disease are the primary catalysts. Traders should monitor for any early data leaks or enrollment updates ahead of the Q4 readout, which will be a binary event for the stock. The cash runway into Q2 2028 provides a long no-dilution window, reducing near-term financing risk.
Price Chart
Executive Summary
First Tracks Biotherapeutics reported Q2 2026 net loss of $33.4M ($0.95/share), narrower than the $42.4M loss in Q2 2025, driven by lower R&D costs post-spin-off. The key catalyst is the FDA Fast Track designation for lead asset ANB033 in celiac disease, with Cohort 1 Phase 1b data on track for Q4 2026 and cash runway reiterated into Q2 2028. The improved loss trajectory and regulatory milestone are positive, but the stock remains a binary event-driven play on clinical data readouts.
Key Financial Metrics
Key Facts
- Q2 2026 net loss narrowed to $33.4M ($0.95/share) from $42.4M ($1.47/share) in Q2 2025
- FDA Fast Track designation granted for ANB033 in celiac disease
- Cash, cash equivalents and investments totaled $168.0M as of June 30, 2026, with runway into Q2 2028
- Top-line Cohort 1 Phase 1b data for ANB033 in celiac disease reaffirmed for Q4 2026
- Cohort 2 enrollment enhanced to up to 40 patients; top-line data anticipated Q1 2027
- Phase 1b trial in eosinophilic esophagitis ongoing; top-line data anticipated Q3 2027
- Plan to initiate Phase 2 trials in two additional indications in H1 2027
- R&D expenses decreased to $25.6M from $39.3M year-over-year due to lower rosnilimab/ANB032 costs offset by ANB033 trial costs
Financial Impact
Net loss improved by 21.4% year-over-year to $33.4M; cash burn rate appears sustainable with $168M runway into Q2 2028
Risk Factors
- Phase 1b data for ANB033 in celiac disease may fail to show efficacy, leading to significant downside
- Competitor registrational data in SLE/CLE (Q4 2026/early 2027) could impact ANB101 development strategy
- Pre-revenue clinical-stage biotech with no approved products; stock is binary on pipeline catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344098 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $43.80 | awaiting T+1 | — | $44.05 (+0.57%) |
Oct 20, 2026 5d ago | 8-K | $42.77 $43.14 | ▲ +0.87% | ▲ +2.05% | $44.05 (+2.99%) |
Oct 15, 2026 10d ago | 8-K | $34.46 $36.28 | ▼ −5.28% | ▼ −4.86% | $44.05 (−27.83%) |
Oct 15, 2026 11d ago | Press Release | $36.04 $34.46 | ▲ +4.38% | ▲ +3.28% | $44.05 (−22.23%) |
Oct 13, 2026 13d ago | 8-K | $31.68 $34.13 | ▲ +7.73% | ▲ +8.81% | $44.05 (+39.05%) |
Aug 12, 2026 10w ago | 8-K | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 12, 2026 10w ago | Press Release | $44.03 $44.04 | ▲ +0.02% | ▲ +0.22% | $44.05 (+0.05%) |
Aug 7, 2026 11w ago | 3/A | $47.92 $46.75 | ▼ −2.44% | ▼ −2.12% | $44.05 (−8.08%) |
Jun 22, 2026 17w ago | 8-K | $17.78 $16.69 | ▼ −6.13% | ▼ −6.08% | $44.05 (+147.75%) |
May 14, 2026 23w ago | 8-K | $16.90 $17.79 | ▲ +5.27% | ▲ +5.33% | $44.05 (+160.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers